Biotech Archives - Page 125 of 795

2 minute read

Nevro To Highlight 25 Scientific Abstracts At 2024 North American Neuromodulation Society Annual Meeting

January 17, 5:20 PM

Presentations review clinical results of 10 kHz Therapy™ for the treatment of chronic backand leg pain, non-surgical back pain (NSBP), and painful diabetic neuropathy (PDN)REDWOOD CITY, Calif., Jan. 17, 2024

NVRO

2 minute read

Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness

By Vandana Singh

January 17, 4:28 PM

Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation.

ABBV

2 minute read

Why Is Cancer Focused Adagene Stock Plummeting Today?

By Vandana Singh

January 17, 12:38 PM

Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in Colorectal Cancer patients. ADAG shares currently down 47.1% at $2.0."

ADAG

2 minute read

Why Is Antibiotic Player Acurx Pharmaceuticals Stock Trading Lower Today?

By Vandana Singh

January 17, 12:26 PM

Acurx Pharmaceuticals' ibezapolstat outperforms vancomycin with a 94% eradication rate. Stay tuned for Q1 2024 updates on Extended Clinical Cure and microbiome data.

ACXP

2 minute read

Cardiff Oncology Announces Publication Of Data From Phase 1b study In Second-Line KRAS-Mutated mCRC In Clinical Cancer Research

By Benzinga Newsdesk

January 17, 11:31 AM

- Findings from the Phase 1b portion of company's Phase 1b/2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care -- These peer-reviewed

CRDF

2 minute read

Precipio Signs Distribution Agreement For IV-Cell And HemeScreen In Japan

By Benzinga Newsdesk

January 17, 11:30 AM

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market. The

PRPO

2 minute read

Eli Lilly’s Blockbuster Diabetes Drug Mounjaro Set To Enter New Markets Amid Manufacturing Boost

By Vandana Singh

January 17, 11:30 AM

Discover Eli Lilly's global expansion plans for weight-loss drug Mounjaro in new countries. CEO David Ricks hints at potential U.K. launch. Explore our strategic manufacturing capacity expansion.

LLY

3 minute read

Better Therapeutics Announces Publication Of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective And Less Costly Than Standard Of Care Alone

By Benzinga Newsdesk

January 17, 10:29 AM

Over a lifetime horizonAspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower costStudy suggests that using AspyreRx can

BTTX

5 minute read

Elicio Therapeutics To Present ELI-002 7P Trial In Progress Poster On Phase 1/2 Study Of Lymph Node-Targeted Vaccine At ASCO GI Symposium

By Benzinga Newsdesk

January 17, 9:33 AM

AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses that correlated with

ELTX

3 minute read

Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors

By Benzinga Newsdesk

January 17, 9:31 AM

Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose LevelKVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers Required